Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer

Conclusions: Although the majority of patients with metastatic TNBC demonstrated PIK3CA mutations in cfDNA, the addition of everolimus to gemcitabine/cisplatin did not have a synergistic effect in these patients. Further studies are needed to determine the most effective way to target the PI3K/AKT/mTOR pathway in TNBC patients.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: In Hae Park, Sun-Young Kong, Youngmee Kwon, Min Kyeong Kim, Sung Hoon Sim, Jungnam Joo, Keun Seok Lee Tags: Research Paper Source Type: research